Stockscreener 앱 받기
5.15
1.90%
-0.10
시간 외 거래:
5.38
0.23
+4.47%
전일 마감가:
$5.25
열려 있는:
$5.32
하루 거래량:
339.11K
Relative Volume:
1.50
시가총액:
$107.76M
수익:
-
순이익/손실:
$-14.88M
주가수익비율:
-5.2551
EPS:
-0.98
순현금흐름:
$-10.29M
1주 성능:
-11.21%
1개월 성능:
-14.45%
6개월 성능:
-12.27%
1년 성능:
-16.53%
1일 변동 폭
$5.01
$5.50
1주일 범위
$5.01
$5.96
52주 변동 폭
$4.65
$8.29
Coya Therapeutics Inc Stock (COYA) Company Profile
명칭
Coya Therapeutics Inc
전화
650.739.3939
주소
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
COYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
5.15 | 109.85M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-09 | 개시 | Lake Street | Buy |
| 2024-12-04 | 개시 | D. Boral Capital | Buy |
Coya Therapeutics Inc 주식(COYA)의 최신 뉴스
Coya Therapeutics: Clinical Momentum, Extended Cash Runway, and DCF-Derived Upside Support Reiterated Buy and $18 Target - TipRanks
Coya Therapeutics (NASDAQ:COYA) Given Buy Rating at D. Boral Capital - Defense World
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for CO - PharmiWeb.com
Coya Therapeutics announces FDA acceptance of COYA 302 IND application - TipRanks
COYA Stock Receives Consistent "Buy" Rating from D. Boral Capita - GuruFocus
D. Boral Capital Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
US COYA 302 trial in ALS expands to Canada after regulatory nod - ALS News Today
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) - The Joplin Globe
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for COYA 302 for the Treatment of Frontotemporal Dementia - MarketScreener
(COYA) Risk Channels and Responsive Allocation - Stock Traders Daily
Coya announces Health Canada acceptance of COYA 302 clinical trial application - MSN
S P Trends: Will Coya Therapeutics Inc stock pay special dividendsJuly 2025 Price Swings & Long-Term Safe Return Strategies - moha.gov.vn
Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - BioSpace
Trading the Move, Not the Narrative: (COYA) Edition - Stock Traders Daily
D. Boral Capital Maintains Coya Therapeutics (COYA) Buy Recommendation - Nasdaq
D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics receives clinical trial application acceptance from Health Canada - marketscreener.com
Coya Therapeutics, Inc. Receives Clinical Trial Application Acceptance from Health Canada to Proceed with the COYA302 Alstars Trial for the Treatment of Amyotrophic Lateral Sclerosis - marketscreener.com
Moving Averages: Why retail investors pile into Coya Therapeutics Inc. stockEarnings Recap Report & Reliable Entry Point Alerts - Улправда
Why retail investors pile into Coya Therapeutics Inc. stock2025 Trading Volume Trends & Low Volatility Stock Recommendations - Улправда
Analyst Upgrade: Is Coya Therapeutics Inc. stock a bargain at current levels2025 Volatility Report & Capital Protection Trading Alerts - DonanımHaber
Can Coya Therapeutics Inc. stock maintain operating marginsJuly 2025 Big Picture & Safe Capital Investment Plans - Улправда
Coya Therapeutics Receives $4.2M Milestone Payment - TipRanks
Coya Therapeutics Receives Milestone Payment for ALS Trial - TradingView — Track All Markets
Coya Therapeutics (NASDAQ: COYA) reports $4.2 million ALS trial payment - Stock Titan
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives $16.00 Average Price Target from Brokerages - Defense World
Coya Therapeutics receives $4.2M milestone payment - MSN
Coya Therapeutics Earnings Notes - Trefis
Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Responsive Playbooks and the COYA Inflection - Stock Traders Daily
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock By Investing.com - Investing.com Canada
Buy Rating for Coya: Phase 2 Trial Initiation and Financial Milestones Boost Prospects - TipRanks
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS - BioSpace
Coya Therapeutics, Inc.: Promising Advancements in ALS and FTD Treatment with COYA-302 - TipRanks
Coya Therapeutics Announces Patients Have Been Dosed in the Alstars Trial of Coya 302 for the Treatment of Als - marketscreener.com
Coya Therapeutics' (COYA) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Eisai Still Confident in Anti-Tau Asset as J&J Becomes Latest Victim in Spiraling Space - BioSpace
Analysts Are Bullish on Top Healthcare Stocks: vTv Therapeutics (VTVT), Theravance Biopharma (TBPH) - The Globe and Mail
Coya Therapeutics (COYA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Understanding the Setup: (COYA) and Scalable Risk - Stock Traders Daily
Investor Presentation (12/01/2025 00: 00 - marketscreener.com
Highs Report: Is Coya Therapeutics Inc. stock a top momentum play2025 Growth vs Value & Advanced Swing Trade Entry Plans - BỘ NỘI VỤ
HC Wainwright Lifts Earnings Estimates for Coya Therapeutics - MarketBeat
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences - BioSpace
Form 424B5Prospectus [Rule 424(b)(5)] - ADVFN
H.C. Wainwright Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛
H.C. Wainwright reaffirms Buy rating on Coya Therapeutics stock at $18 target - Investing.com Canada
Coya Therapeutics: Strong Financial Position and Upcoming Catalysts Support Buy Rating - TipRanks
What drives Coya Therapeutics Inc stock pricePortfolio Risk Assessment & Outstanding Growth Portfolio - earlytimes.in
D. Boral Capital Initiates Coverage of Coya Therapeutics (COYA) with Buy Recommendation - MSN
Coya Therapeutics Inc (COYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):